Intensive antiplatelet treatment is beneficial after confirmation of anatomic coronary disease by angiography

Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial

Literature - Wiviott SD, White HD, Ohman EM et al. - Lancet, Volume 382, Issue 9892, Pages 605 - 613

Wiviott SD, White HD, Ohman EM et al
Lancet, Volume 382, Issue 9892, Pages 605 - 613


Many patients with unstable angina or non-ST-segment elevation myocardial infarction (UA/NSTEMI) are managed without revascularization [1,2] , despite it being recommended [3,4]. Treatment with two antiplatelet drugs is also a cornerstone of management of UA/NSTEMI. Often a combination of aspirin and a PsY12 antagonist is given, irrespective of whether treatment involves revascularisation. This combination was found to be better in comparison to clopidogrel and aspirin [5,6].
In the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial, patients were assigned randomly to treatment with clopidogrel or prasugrel. This study assessed outcomes based on assigned treatment and whether or not patients had pre-enrolment coronary angiography. The primary endpoint was cardiovascular death, myocardial infarction (MI) or stroke at 30 months.

Main results

  • Baseline characteristics  differed between those who received coronary angiography and those who did not.
  • Patients who had angiography before enrolment (281/3085, 12.8%)more often reached the primary endpoint than did patients who did have angiography (480/4158, 16.5%, adj HR for angiography: 0.63, 95%CI: 0.53-0.75, P<0.0001). Patients who had angiography also showed less cardiovascular death or all-cause death, and MI, while GUSTO and TIMI bleeding were not different between groups.
  • Subsequent angiography and revascularisation during the trial did not occur often, in either group. Percutaneous coronary intervention was also similarly rare in both groups. Coronary artery bypass graft was performed less frequent in patients who had angiography before enrolment (1.3% vs. 3.2%, HR: 0.39, 95%CI: 0.27-0.56, P<0.0001).
  • Of the patients who received angiography, fewer patients assigned to prasugrel reached the primary endpoint at 30 months, as compared to those receiving clopidogrel (10.7% vs. 14.9%, HR: 0.77, 95%CI: 0.61-0.98, P=0.032). No difference between treatments was seen for patients who had no angiography.
  • When assessing all events, prasugrel was associated with fewer events in patients who had received angiography, while no difference was seen in patients who did not have angiography. Similar results were seen when considering MI and stroke as endpoints. Risk of cardiovascular death was not different between treatments, irrespective of whether patients had had angiography.
  • The proportion of patients with bleeding events was higher among those who received prasugrel, with or without angiography, but no difference between treatment groups was seen for frequency of severe GUSTO and TIMI bleedings.


Among patients who had angiography, those treated with prasugrel had fewer CV deaths, MI or stroke than those who took clopidogrel. Differences in baseline characteristics likely contributed to the differences in clinical outcomes: higher rates of post-acute coronary syndrome events are seen, but not events that are modifiable by antiplatelet drugs. Angiography without revascularisation is not expected to reduce CV events, thus the difference in recurrent CV events seems to be a result of the different risk profiles, rather than the effect of treatment.
Therefore, these data do not suggest that giving angiography to more patients will improve CV outcome. Angiography may however help to identify patients who have coronary disease. When angiography has confirmed anatomic coronary disease, the benefits and risks of intensive antiplatelet treatment remain, whether drug treatment of PCI is chosen.


1 Peterson ED, Roe MT, Chen AY, et al. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart 2010; 96: 1798–802.
2 Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096–104.
3 Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875–910.
4 Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European
Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
5 Wiv iott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
6 Wal lentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57.

Find this article on Pubmed

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free